APO Research
Talk to an analyst

APO RESEARCH · REPORT

HIV and AIDS Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global HIV and AIDS Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025181 pages

Choose your research edition.

Industry ResearchHIV and AIDS Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal HIV and AIDS Vaccine Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal HIV and AIDS Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HIV and AIDS Vaccine Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal HIV and AIDS Vaccine Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global HIV and AIDS Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for HIV and AIDS Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for HIV and AIDS Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for HIV and AIDS Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for HIV and AIDS Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of HIV and AIDS Vaccine include HKUMed, Sanofi-Pasteur, Johnson and Johnson (Janssen), IAVI, Uvax Bio and AELIX Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global HIV and AIDS Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of HIV and AIDS Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents HIV and AIDS Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the HIV and AIDS Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

HIV and AIDS Vaccine Segment by Company

HKUMed

Sanofi-Pasteur

Johnson and Johnson (Janssen)

IAVI

Uvax Bio

AELIX Therapeutics

HIV and AIDS Vaccine Segment by Type

Preventive Vaccine

Therapeutic Vaccine

HIV and AIDS Vaccine Segment by Application

Viral Vector Vaccines

Nucleic Acid Vaccines (including mRNA Vaccines)

Recombinant Protein Vaccines

Other Vaccines

HIV and AIDS Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV and AIDS Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HIV and AIDS Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV and AIDS Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the HIV and AIDS Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of HIV and AIDS Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of HIV and AIDS Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of HIV and AIDS Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. HIV and AIDS Vaccine Industry Trends Table 2. HIV and AIDS Vaccine Industry Drivers Table 3. HIV and AIDS Vaccine Industry Opportunities and Challenges Table 4. HIV and AIDS Vaccine Industry Restraints Table 5. Global HIV and AIDS Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global HIV and AIDS Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global HIV and AIDS Vaccine Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global HIV and AIDS Vaccine Sales Market Share by Manufacturers Table 9. Global HIV and AIDS Vaccine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global HIV and AIDS Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global HIV and AIDS Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global HIV and AIDS Vaccine Manufacturers, Product Type & Application Table 13. Global HIV and AIDS Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global HIV and AIDS Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Preventive Vaccine Table 17. Major Manufacturers of Therapeutic Vaccine Table 18. Global HIV and AIDS Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units) Table 20. Global HIV and AIDS Vaccine Sales by Type (2027-2032) & (K Units) Table 21. Global HIV and AIDS Vaccine Sales Market Share by Type (2021-2026) Table 22. Global HIV and AIDS Vaccine Sales Market Share by Type (2027-2032) Table 23. Global HIV and AIDS Vaccine Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global HIV and AIDS Vaccine Revenue by Type (2021-2026) & (K Units) Table 25. Global HIV and AIDS Vaccine Revenue by Type (2027-2032) & (K Units) Table 26. Global HIV and AIDS Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global HIV and AIDS Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Viral Vector Vaccines Table 29. Major Manufacturers of Nucleic Acid Vaccines (including mRNA Vaccines) Table 30. Major Manufacturers of Recombinant Protein Vaccines Table 31. Major Manufacturers of Other Vaccines Table 32. Global HIV and AIDS Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units) Table 34. Global HIV and AIDS Vaccine Sales by Application (2027-2032) & (K Units) Table 35. Global HIV and AIDS Vaccine Sales Market Share by Application (2021-2026) Table 36. Global HIV and AIDS Vaccine Sales Market Share by Application (2027-2032) Table 37. Global HIV and AIDS Vaccine Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global HIV and AIDS Vaccine Revenue by Application (2021-2026) & (K Units) Table 39. Global HIV and AIDS Vaccine Revenue by Application (2027-2032) & (K Units) Table 40. Global HIV and AIDS Vaccine Revenue Market Share by Application (2021-2026) Table 41. Global HIV and AIDS Vaccine Revenue Market Share by Application (2027-2032) Table 42. Global HIV and AIDS Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global HIV and AIDS Vaccine Sales by Region (2021-2026) & (K Units) Table 44. Global HIV and AIDS Vaccine Sales Market Share by Region (2021-2026) Table 45. Global HIV and AIDS Vaccine Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global HIV and AIDS Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 47. North America HIV and AIDS Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units) Table 49. North America HIV and AIDS Vaccine Sales by Country (2027-2032) & (K Units) Table 50. Europe HIV and AIDS Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units) Table 52. Europe HIV and AIDS Vaccine Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific HIV and AIDS Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific HIV and AIDS Vaccine Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa HIV and AIDS Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa HIV and AIDS Vaccine Sales by Country (2027-2032) & (K Units) Table 59. Global HIV and AIDS Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global HIV and AIDS Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 61. Global HIV and AIDS Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 62. Global HIV and AIDS Vaccine Revenue Market Share by Region (2021-2026) Table 63. Global HIV and AIDS Vaccine Revenue Market Share by Region (2027-2032) Table 64. HKUMed Company Information Table 65. HKUMed Business Overview Table 66. HKUMed HIV and AIDS Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. HKUMed HIV and AIDS Vaccine Product Portfolio Table 68. HKUMed Recent Development Table 69. Sanofi-Pasteur Company Information Table 70. Sanofi-Pasteur Business Overview Table 71. Sanofi-Pasteur HIV and AIDS Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Sanofi-Pasteur HIV and AIDS Vaccine Product Portfolio Table 73. Sanofi-Pasteur Recent Development Table 74. Johnson and Johnson (Janssen) Company Information Table 75. Johnson and Johnson (Janssen) Business Overview Table 76. Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Johnson and Johnson (Janssen) HIV and AIDS Vaccine Product Portfolio Table 78. Johnson and Johnson (Janssen) Recent Development Table 79. IAVI Company Information Table 80. IAVI Business Overview Table 81. IAVI HIV and AIDS Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. IAVI HIV and AIDS Vaccine Product Portfolio Table 83. IAVI Recent Development Table 84. Uvax Bio Company Information Table 85. Uvax Bio Business Overview Table 86. Uvax Bio HIV and AIDS Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Uvax Bio HIV and AIDS Vaccine Product Portfolio Table 88. Uvax Bio Recent Development Table 89. AELIX Therapeutics Company Information Table 90. AELIX Therapeutics Business Overview Table 91. AELIX Therapeutics HIV and AIDS Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. AELIX Therapeutics HIV and AIDS Vaccine Product Portfolio Table 93. AELIX Therapeutics Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. HIV and AIDS Vaccine Distributors List Table 97. HIV and AIDS Vaccine Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. HIV and AIDS Vaccine Product Image Figure 2. Global HIV and AIDS Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HIV and AIDS Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global HIV and AIDS Vaccine Sales (2021-2032) & (K Units) Figure 5. Global HIV and AIDS Vaccine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 HIV and AIDS Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Preventive Vaccine Image Figure 9. Therapeutic Vaccine Image Figure 10. Global HIV and AIDS Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global HIV and AIDS Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global HIV and AIDS Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global HIV and AIDS Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global HIV and AIDS Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global HIV and AIDS Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Viral Vector Vaccines Image Figure 17. Nucleic Acid Vaccines (including mRNA Vaccines) Image Figure 18. Recombinant Protein Vaccines Image Figure 19. Other Vaccines Image Figure 20. Global HIV and AIDS Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global HIV and AIDS Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global HIV and AIDS Vaccine Sales Market Share by Application (2021-2032) Figure 23. Global HIV and AIDS Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global HIV and AIDS Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global HIV and AIDS Vaccine Revenue Market Share by Application (2021-2032) Figure 26. North America HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America HIV and AIDS Vaccine Sales Market Share by Country (2021-2032) Figure 28. U.S. HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe HIV and AIDS Vaccine Sales Market Share by Country (2021-2032) Figure 33. Germany HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific HIV and AIDS Vaccine Sales Market Share by Country (2021-2032) Figure 40. China HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa HIV and AIDS Vaccine Sales Market Share by Country (2021-2032) Figure 48. Brazil HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile HIV and AIDS Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global HIV and AIDS Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global HIV and AIDS Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Figure 59. North America HIV and AIDS Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. Europe HIV and AIDS Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific HIV and AIDS Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa HIV and AIDS Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. HIV and AIDS Vaccine Value Chain Figure 67. Manufacturing Cost Structure Figure 68. HIV and AIDS Vaccine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Preventive Vaccine
  • Therapeutic Vaccine
Applications
  • Viral Vector Vaccines
  • Nucleic Acid Vaccines (including mRNA Vaccines)
  • Recombinant Protein Vaccines
  • Other Vaccines
Companies covered
  • HKUMed
  • Sanofi-Pasteur
  • Johnson and Johnson (Janssen)
  • IAVI
  • Uvax Bio
  • AELIX Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global HIV and AIDS Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global HIV and AIDS Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global HIV and AIDS Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global HIV and AIDS Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global HIV and AIDS Vaccine Market Dynamics
  1. 2.1 HIV and AIDS Vaccine Industry Trends
  2. 2.2 HIV and AIDS Vaccine Industry Drivers
  3. 2.3 HIV and AIDS Vaccine Industry Opportunities and Challenges
  4. 2.4 HIV and AIDS Vaccine Industry Restraints
3 HIV and AIDS Vaccine Market by Manufacturers
  1. 3.1 Global HIV and AIDS Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global HIV and AIDS Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global HIV and AIDS Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global HIV and AIDS Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global HIV and AIDS Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global HIV and AIDS Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global HIV and AIDS Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global HIV and AIDS Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 HIV and AIDS Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 HIV and AIDS Vaccine Tier 1, Tier 2, and Tier 3
4 HIV and AIDS Vaccine Market by Type
  1. 4.1 HIV and AIDS Vaccine Type Introduction
  2. 4.1.1 Preventive Vaccine
  3. 4.1.2 Therapeutic Vaccine
  4. 4.2 Global HIV and AIDS Vaccine Sales by Type
  5. 4.2.1 Global HIV and AIDS Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global HIV and AIDS Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global HIV and AIDS Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global HIV and AIDS Vaccine Revenue by Type
  9. 4.3.1 Global HIV and AIDS Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global HIV and AIDS Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global HIV and AIDS Vaccine Revenue Market Share by Type (2021-2032)
5 HIV and AIDS Vaccine Market by Application
  1. 5.1 HIV and AIDS Vaccine Application Introduction
  2. 5.1.1 Viral Vector Vaccines
  3. 5.1.2 Nucleic Acid Vaccines (including mRNA Vaccines)
  4. 5.1.3 Recombinant Protein Vaccines
  5. 5.1.4 Other Vaccines
  6. 5.2 Global HIV and AIDS Vaccine Sales by Application
  7. 5.2.1 Global HIV and AIDS Vaccine Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global HIV and AIDS Vaccine Sales by Application (2021-2032)
  9. 5.2.3 Global HIV and AIDS Vaccine Sales Market Share by Application (2021-2032)
  10. 5.3 Global HIV and AIDS Vaccine Revenue by Application
  11. 5.3.1 Global HIV and AIDS Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global HIV and AIDS Vaccine Revenue by Application (2021-2032)
  13. 5.3.3 Global HIV and AIDS Vaccine Revenue Market Share by Application (2021-2032)
6 Global HIV and AIDS Vaccine Sales by Region
  1. 6.1 Global HIV and AIDS Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global HIV and AIDS Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global HIV and AIDS Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global HIV and AIDS Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America HIV and AIDS Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America HIV and AIDS Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe HIV and AIDS Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe HIV and AIDS Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific HIV and AIDS Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific HIV and AIDS Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa HIV and AIDS Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa HIV and AIDS Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global HIV and AIDS Vaccine Revenue by Region
  1. 7.1 Global HIV and AIDS Vaccine Revenue by Region
  2. 7.1.1 Global HIV and AIDS Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global HIV and AIDS Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global HIV and AIDS Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global HIV and AIDS Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America HIV and AIDS Vaccine Revenue (2021-2032)
  8. 7.2.2 North America HIV and AIDS Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe HIV and AIDS Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe HIV and AIDS Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific HIV and AIDS Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific HIV and AIDS Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa HIV and AIDS Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa HIV and AIDS Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 HKUMed
  2. 8.1.1 HKUMed Company Information
  3. 8.1.2 HKUMed Business Overview
  4. 8.1.3 HKUMed HIV and AIDS Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 HKUMed HIV and AIDS Vaccine Product Portfolio
  6. 8.1.5 HKUMed Recent Developments
  7. 8.2 Sanofi-Pasteur
  8. 8.2.1 Sanofi-Pasteur Company Information
  9. 8.2.2 Sanofi-Pasteur Business Overview
  10. 8.2.3 Sanofi-Pasteur HIV and AIDS Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi-Pasteur HIV and AIDS Vaccine Product Portfolio
  12. 8.2.5 Sanofi-Pasteur Recent Developments
  13. 8.3 Johnson and Johnson (Janssen)
  14. 8.3.1 Johnson and Johnson (Janssen) Company Information
  15. 8.3.2 Johnson and Johnson (Janssen) Business Overview
  16. 8.3.3 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Product Portfolio
  18. 8.3.5 Johnson and Johnson (Janssen) Recent Developments
  19. 8.4 IAVI
  20. 8.4.1 IAVI Company Information
  21. 8.4.2 IAVI Business Overview
  22. 8.4.3 IAVI HIV and AIDS Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 IAVI HIV and AIDS Vaccine Product Portfolio
  24. 8.4.5 IAVI Recent Developments
  25. 8.5 Uvax Bio
  26. 8.5.1 Uvax Bio Company Information
  27. 8.5.2 Uvax Bio Business Overview
  28. 8.5.3 Uvax Bio HIV and AIDS Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Uvax Bio HIV and AIDS Vaccine Product Portfolio
  30. 8.5.5 Uvax Bio Recent Developments
  31. 8.6 AELIX Therapeutics
  32. 8.6.1 AELIX Therapeutics Company Information
  33. 8.6.2 AELIX Therapeutics Business Overview
  34. 8.6.3 AELIX Therapeutics HIV and AIDS Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AELIX Therapeutics HIV and AIDS Vaccine Product Portfolio
  36. 8.6.5 AELIX Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 HIV and AIDS Vaccine Value Chain Analysis
  2. 9.1.1 HIV and AIDS Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 HIV and AIDS Vaccine Production Mode & Process
  6. 9.2 HIV and AIDS Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 HIV and AIDS Vaccine Distributors
  9. 9.2.3 HIV and AIDS Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst